Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies

C Claudia V. Perez Almeria (Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam) O Omolade Otun R Roman Schlimgen T Thomas D. Lamme L Lotte Di Niro C Caitrin Crudden (Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam) J Jan Paul Bebelman N Noureldine Youssef L Lejla Musli S Shawn Jenjak V Vladimir Bobkov J Julia Drube C Carsten Hoffmann B Brian F. Volkman S Sébastien Granier C Cherine Bechara M Marco Siderius (Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam) R Raimond Heukers (Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam) C Christopher T. Schafer M Martine J. Smit

Abstract

Abstract Stimulation of atypical chemokine receptor 3 (ACKR3) by chemokines does not activate G proteins but recruits arrestin. It is a chemokine scavenger that indirectly influences responses by restricting the availability of CXCL12, an agonist shared with the canonical receptor CXCR4. ACKR3 is upregulated in numerous disorders. Due to limited insights in chemokine-activated ACKR3 signaling, it is unclear how ACKR3 contributes to pathological phenotypes. One explanation may be that constitutive activity of ACKR3 drives non-canonical signaling through a basal receptor state. Here we characterize the constitutive responses of ACKR3 using inverse agonistic nanobodies to suppress its basal activity. These tools promote an inactive receptor conformation which decreased arrestin engagement and inhibited constitutive internalization. Basal non-chemotactic, cancer cell motility was also suppressed, suggesting a role for ACKR3 in this process. The basal receptor activity in pathophysiology may provide an alternate therapeutic approach for targeting ACKR3.

Article Details

Volume / Issue Vol. 16, Issue 1
Published December 02, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (20)

C

Claudia V. Perez Almeria

Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam

O

Omolade Otun

R

Roman Schlimgen

T

Thomas D. Lamme

L

Lotte Di Niro

C

Caitrin Crudden

Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam

J

Jan Paul Bebelman

N

Noureldine Youssef

L

Lejla Musli

S

Shawn Jenjak

V

Vladimir Bobkov

J

Julia Drube

C

Carsten Hoffmann

B

Brian F. Volkman

S

Sébastien Granier

C

Cherine Bechara

M

Marco Siderius

Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam

R

Raimond Heukers

Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam

C

Christopher T. Schafer

M

Martine J. Smit